Abdelkader Hamdy, Al-Fatease Adel, Alamri Ali H, Shoman Mai E, Abdel-Bar Hend Mohamed, Fathalla Zeinab
Central Labs, King Khalid University, AlQura'a, Abha, P.O. Box 960, Saudi Arabia.
Department of Pharmaceutics, College of Pharmacy, King Khalid University, Abha 62529, Saudi Arabia.
Int J Pharm X. 2025 May 9;9:100336. doi: 10.1016/j.ijpx.2025.100336. eCollection 2025 Jun.
With advancements in drug repurposing, the search for effective and less harmful anticancer agents remains a critical endeavor. Raloxifene, although not a typical anticancer drug, holds promise in this context. However, its poor solubility poses a significant challenge to its therapeutic potential and formulation efficiency. Functional excipients such as cyclodextrins (e.g., β-cyclodextrin, hydroxy propyl β-cyclodextrin, and Captisol) and pH-modifying excipients (e.g., tartaric acid, azelaic acid, and arginine) were investigated to enhance solubility, dissolution, cytotoxicity and cellular uptakes employing Caco-2 cell lines through binary solid dispersions. In silico studies suggested the potential for salt formation with raloxifene-azelaic acid and raloxifene-tartaric acid, as well as inclusion complexes with cyclodextrins. Experimental results showed that pH-modifying excipients, particularly tartaric and azelaic acids, significantly improved solubility (up to an 800-fold increase), outperforming cyclodextrins (8-fold increase) compared to the untreated drug. Cytotoxicity studies on the human breast cancer (Michigan cancer foundation, MCF-7) cells revealed that raloxifene-tartaric acid significantly enhanced cell killing, achieving efficacy comparable to the standard anticancer drug Taxol. Additionally, both fluorescence-labeled raloxifene: hydroxy propyl β-cyclodextrin coprecipitated mixtures (Coppt) and raloxifene: tartaric acid Coppt exhibited concentration- and time-dependent cellular uptake, with mean fluorescence intensity increasing significantly at 24 h, indicating rapid internalization and sustained intracellular retention, especially at higher concentrations. More interestingly, the superior cellular uptake was in favor of the latter, indicating the pH-modifying excipient tartaric acid, and these findings correlated well with solubility and dissolution studies.
随着药物重新利用领域的进展,寻找有效且危害较小的抗癌药物仍然是一项至关重要的工作。雷洛昔芬虽然不是典型的抗癌药物,但在这方面具有潜力。然而,其溶解度差对其治疗潜力和制剂效率构成了重大挑战。研究了功能性辅料如环糊精(如β-环糊精、羟丙基β-环糊精和Captisol)和pH调节辅料(如酒石酸、壬二酸和精氨酸),通过二元固体分散体提高雷洛昔芬在Caco-2细胞系中的溶解度、溶出度、细胞毒性和细胞摄取。计算机模拟研究表明,雷洛昔芬与壬二酸、酒石酸形成盐以及与环糊精形成包合物具有可能性。实验结果表明,pH调节辅料,尤其是酒石酸和壬二酸,显著提高了溶解度(提高了800倍),与未处理的药物相比,其效果优于环糊精(提高了8倍)。对人乳腺癌(密歇根癌症基金会,MCF-7)细胞的细胞毒性研究表明,雷洛昔芬-酒石酸显著增强了细胞杀伤作用,其疗效与标准抗癌药物紫杉醇相当。此外,荧光标记的雷洛昔芬:羟丙基β-环糊精共沉淀混合物(Coppt)和雷洛昔芬:酒石酸Coppt均表现出浓度和时间依赖性的细胞摄取,平均荧光强度在24小时时显著增加,表明快速内化和持续的细胞内保留,尤其是在较高浓度下。更有趣的是,后者的细胞摄取效果更好,表明pH调节辅料酒石酸具有优势,这些发现与溶解度和溶出度研究结果密切相关。